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examined the news reports from online journals, websites, and reputable news 
outlets to determine the most likely reason for drug failure. RESULTS: Of 31 
products included in the analysis 16 failed to meet the expectations announced 
in the month prior to launch. We attributed price or reimbursement as the 
reason that seven of the 16 products failed to meet market expectations. 
Competition due to existing product dominance, near-simultaneous launches for 
the same patient population, and widely available generics explained the failure 
of five products. Efficacy questions and label restrictions contributed to the slow 
uptake of three products. Capacity can be faulted on another product. 
CONCLUSIONS: As the landscape changes, manufacturers must consider 
product differentiation and market assessment early to anticipate the market’s 
price threshold to avoid a key pitfall in new product launches.  
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OBJECTIVES: While many small biotechs are acquired by larger pharmaceuticals, 
few attempt a full scale commercialization of their product. We analyzed the 
stock market returns of three small, single drug bio-technology firms which had 
drugs approved by the FDA in 2010. METHODS: The historical prices adjusted for 
corporate action were used for all three firms from Q4 2007 through Q3 2012 
which accounted for 1,261 trading days per company. All products have been 
approved by the FDA for at least 8 quarters. Each company’s prices were broken 
up into daily and quarterly intervals as well as pre-launch and post-launch. 
Simple statistics and t-tests were run on the stock returns for all intervals. 
RESULTS: On average, the pooled total return associated with the pre-launch 
phase was 212.6% higher than post-launch. The average pooled quarterly and 
daily returns during the pre-launch period were 19.1% and .37% higher than the 
post-launch period, respectively. The standard deviation of the daily returns 
during the pre-launch period was on average 24% higher than during the post-
launch period. A two-tail t-test assuming unequal variances was run on each of 
the daily stock prices with a hypothesized mean difference of 0 between pre-
launch and post-launch, for all three of the companies the p-value was <0.05. 
CONCLUSIONS: Investors seemed to prefer the pre-launch period which received 
a greater return on investment. The difference in the mean prices for each 
company in the different phases was statistically significant. However this 
analysis is relatively early in the post-launch term for each drug as smaller 
companies tend to gain market share more slowly than larger pharmaceuticals. 
The stock returns of these companies seem to be highest in the pre-launch 
phase as opposed to post-launch.  
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OBJECTIVES: To describe the trends in published comparative cost analyses from 
2010 through 2012 for interventions in cancer (CA), diabetes (DM), and 
cardiovascular diseases (CVD). METHODS: A PubMed search of articles published 
between January 2010 and December 2012 was conducted utilizing the following 
search strategy/terms: (cost-effectiveness OR cost-utility OR cost-benefit) AND 
(cancer OR diabetes OR cardiovascular diseases). Articles were excluded if they: 
1) did not contain sufficient information to determine the type of analysis 
conducted; 2) focused on a sequelae of a treatment; 3) no comparative analysis 
was conducted; 4) only costs were considered; or 5) were reviews, editorials, or 
commentaries. The abstracts of the articles, not the full articles themselves, 
were evaluated and used to classify comparative economic analyses by disease 
focus, intervention type, intervention target (e.g., treatment, prevention), 
economic analysis performed, geographic region of population/perspective of the 
analysis, and primary/corresponding author affiliations. Descriptive statistics 
were conducted in PASW Statistics 18.0. RESULTS: The initial search yielded 
3,868 abstracts. Of these, 725 studies were retained in the final analysis (254 in 
2010, 226 in 2011, 245 in 2012). In 2010, 2011 and 2012, respectively, 134, 119, 150 
studies were in CA, 25, 23, 35 in DM, and 95, 84, 60 in CVD. Approximately 63.7% 
of studies across years focused on active treatment or secondary prevention. A 
pharmaceutical, vaccine, or lifestyle intervention was the focus in 47.9% of 
studies. A majority (70.2%) of the studies utilized cost-utility analyses, which was 
consistent across all years, with most study populations/study perspective in 
European countries. CONCLUSIONS: Comparative economic analyses from 2010-
2012 had a heavy focus on active or secondary interventions in CA and in 
European populations. As value-based pricing and health care reform emerges, 
more extensive utilization and publication of comparative cost effectiveness 
analyses will be required.  
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OBJECTIVES: The Health and Economics Bulletin is an electronic periodic of The 
Brazilian Health Surveillance Agency (ANVISA). It aims to provide information to 
health care decision-makers and patients when there is more than one 
pharmaceutical option to treat the same disease and there is no scientific 
evidence of superiority in terms of safety and efficacy among drugs. This bulletin 
intends to improve health care efficiency when it points out the differences on 
treatment costs among the drugs. The objective of this study is to analyze all 
editions of The Health and Economics Bulletin available on ANVISA website. 
METHODS: Data were collected from editions of Health and Economics Bulletin 
published since August 2009 (month of launch) until September 2012. The 
variables considered were: number and type of diseases, therapeutic classes, 
active substance, drugs and treatment costs. RESULTS: Eight editions of the 
bulletin were published and each number addressed a different disease such as 
osteoporosis, glaucoma, gastroesophageal reflux, arterial hypertension, epilepsy, 
dyslipidemia, erectile dysfunction and allergic rhinitis. In total, 12 therapeutic 
classes were evaluated which comprises biphosphonates and oral 
antihistamines on osteoporoses and allergic rhinitis editions, respectively. A 
total of 33 active substances and 64 drugs were assessed, including generics, 
similars and brand drugs. Sixty four costs of treatment were performed which 
demonstrated considerable differences between drugs prescribed for the same 
disease. For example, on the allergic rhinitis edition, it was found 231% of 
difference on treatment costs between the most expensive and the lowest cost 
drugs although they have similar safety and efficacy levels, based on scientific 
evidences. CONCLUSIONS: The Health and Economics Bulletin is an important 
information tool and was elaborated to improve the critical view of health care 
decision-makers and patients. Considering differences of treatment costs among 
drugs that have the same safety and efficacy, they can select the drugs more 
efficiently.  
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OBJECTIVES: The amount of time spent in different activities by inpatient order 
entry pharmacists in a computerized provider order entry (CPOE) versus a non-
CPOE setting. METHODS: A prospective, pretest-posttest, time and motion study 
design was used to compare the workflow of order entry pharmacists in an 
inpatient hospital setting. Randomized data collection was conducted at two 
time periods in the same hospital: the pretest period was immediately before 
implementation of the CPOE system and the posttest period was 5.5 months 
post-implementation. A pre-validated data recording instrument was used to 
record 37 different pharmacist tasks, which were grouped into four activities: 
clinical, distributive, administrative, and miscellaneous. Comparisons of the 
amount of time spent by the order entry pharmacist per hour in each of the four 
different activities were conducted. SAS® version 9.3 was used to analyze the 
data, with statistical significance set at 0.05. RESULTS: A total of 37 hours were 
collected pre-intervention, and 42 hours post-intervention. The amount of time 
(mean number of minutes per hour±SD pre-intervention versus post-
intervention, p-value) for the activities were: clinical (2.0±3.8 vs. 1.9±2.6, p=0.89); 
distributive (45.2±11.3 vs. 49.3±8.1, p=0.11); administrative (10.6±9.8 vs. 6.0±6.5, 
p<0.05); and miscellaneous (2.1±3.2 vs. 2.8± 4.0, p=0.64). CONCLUSIONS: Less time 
was spent by order entry pharmacists in the administrative activity after the 
implementation of CPOE, which translates to more pharmacist time spent in 
other activities. Management should to be aware of the implications of CPOE 
implementation on pharmacist workflow.  
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OBJECTIVES: When developing technology appraisals guidance, NICE (National 
Institute for Health and Clinical Excellence) commissions an independent 
academic centre to critically appraise the manufacturer's submission and 
prepare an Evidence Review Group (ERG) report that reviews the published 
evidence on the relevant technology. NICE has used 11 different academic 
centres to support the work of appraisal committees in the Single Technology 
Appraisal (STA) process and this research aimed to explore whether there were 
differences in acceptance rates between these centres. METHODS: All final 
appraisal determinations (FADs) resulting from STA processes were identified 
(August 2006 – December 2012) from which the recommendation and the 
appraising academic centre were extracted. Acceptance rates were compared 
across the 8 academic centres that made at least 5 recommendations using a Chi 
squared test. RESULTS: This research considered 94 submissions, from which 
106 recommendations were generated. The number of acceptances or rejections 
was not found to differ significantly by centre (p=0.810). Of these centres, the 
highest proportion of NICE positive recommendations followed ERG appraisals 
by Southampton (86%) and the lowest proportion by Liverpool (61%). In between 
were Peninsula (78%), York (77%), Sheffield (76%), Aberdeen (67%), Kleijnen (67%), 
and Birmingham (62%). Nevertheless, the considered therapy areas substantially 
varied between different academic centres, with certain therapy areas being 
preferentially or even exclusively appraised by specific centres. Oncology was 
the most commonly-appraised area overall (47% of recommendations) and the 
appraisal of oncology submissions was not evenly distributed between the 
different academic centres (P<0.001). There were no significant variations in the 
distribution of orphan drugs assessed or in the proportion of restricted 
recommendations issued. CONCLUSIONS: Despite large variations in therapy 
areas considered, the likelihood of a positive recommendation does not appear 
